Concepedia

Grant Toland

GT

Statistics

Publications

4

Citations

1.1K

H-Index

4

Active since

2015

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Grant Toland is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in oncology, pathology, and medicine.

Top concepts

Publications per year

2015–2016

4

Publications

4

Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in Melanoma

Adil Daud, Jedd D. Wolchok, Caroline Robert et al. · Journal of Clinical Oncology · 2016 · 661 citations · Full text

, , +18

Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non–Small-cell Lung Cancer

Charlotte Roach, Nancy R. Zhang, Ellie Corigliano et al. · Applied immunohistochemistry & molecular morphology · 2016 · 348 citations · Full text

, , +17

Development of a Companion Diagnostic for Pembrolizumab in Non–Small Cell Lung Cancer Using Immunohistochemistry for Programmed Death Ligand-1

Marisa Dolled‐Filhart, Charlotte Roach, Grant Toland et al. · Archives of Pathology & Laboratory Medicine · 2016 · 115 citations

Development of a PD-L1 immunohistochemistry (IHC) assay for use as a companion diagnostic for pembrolizumab (MK-3475) in non-small cell lung cancer (NSCLC).

Marisa Dolled‐Filhart, Charlotte Roach, Grant Toland et al. · Journal of Clinical Oncology · 2015 · 10 citations

, , +17

1–4 of 4